Curated News
By: NewsRamp Editorial Staff
September 11, 2025
Sigyn Therapeutics Appoints Apheresis Expert to Advance Cardiovascular Treatment
TLDR
- Sigyn Therapeutics gains competitive edge by appointing Dr. Christoph Zaba to its advisory board, leveraging his expertise to advance cardiovascular disease treatments.
- Sigyn Therapy uses whole blood adsorption on dialysis machines to reduce Lp(a) and LDL-C levels, potentially cutting cardiovascular events by 55-98%.
- Sigyn's technology expands access to life-saving cardiovascular treatments from 60 specialized centers to 7,500 dialysis clinics, improving global health outcomes.
- Sigyn Therapeutics combines dialysis and apheresis to simultaneously target cholesterol and inflammation, pioneering a novel approach to combat heart disease.
Impact - Why it Matters
This development matters because cardiovascular disease remains the leading cause of death globally, affecting millions of people worldwide. The expansion of accessible treatment options through technologies like Sigyn Therapy™ could revolutionize cardiovascular care by making life-saving apheresis treatments available in thousands of dialysis clinics rather than just a few dozen specialized centers. For patients with high lipoprotein levels and cardiovascular risk, this technology could significantly reduce the incidence of heart attacks, strokes, and other major adverse events. The involvement of an experienced medical technology leader like Dr. Zaba accelerates the potential commercialization of this innovative therapy, which could ultimately save lives and reduce healthcare costs associated with cardiovascular complications.
Summary
Sigyn Therapeutics, Inc., a medical technology company developing dialysis-like therapies for cardiovascular disease and cancer, has announced the strategic appointment of Dr. Christoph Zaba to its Scientific Advisory Board. Dr. Zaba brings extensive expertise in medical technology and extracorporeal therapies from his tenure at Fresenius Medical Care, where he directed global product management in therapeutic apheresis. His background includes advancing treatments across nephrology, dermatology, neurology, and cardiovascular medicine, particularly immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for removing pathogenic lipoproteins from blood.
The company's flagship innovation, Sigyn Therapy™, is a first-in-class whole blood adsorption technology designed to simultaneously reduce lipoprotein(a) [Lp(a)] and low-density lipoprotein cholesterol [LDL-C] while targeting inflammatory molecules that fuel cardiovascular disease progression. This approach builds upon the proven benefits of lipoprotein apheresis, which clinical studies show can reduce major adverse cardiovascular events by 55% to 98%. Unlike traditional apheresis treatments limited to approximately 60 specialized centers in the U.S., Sigyn Therapy™ is engineered for use on existing dialysis machines available in roughly 7,500 dialysis clinics nationwide, potentially dramatically expanding treatment access.
Sigyn Therapeutics recently disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease patients with end-stage renal disease. The successful completion of this study could pave the way for a pivotal efficacy study necessary for potential market clearance. Beyond cardiovascular applications, the company is also developing complementary cancer therapies including ImmunePrep™, ChemoPrep™, and ChemoPure™ designed to optimize immunotherapy delivery, enhance chemotherapy targeting, and reduce treatment toxicity through joint venture development relationships.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn Therapeutics Appoints Apheresis Expert to Advance Cardiovascular Treatment
